← Browse by Condition
Medical Condition

recurrent meningioma

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for recurrent meningioma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — recurrent meningioma Clinical Trials

How many clinical trials are currently recruiting for recurrent meningioma?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for recurrent meningioma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for recurrent meningioma?
recurrent meningioma research spans Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a recurrent meningioma clinical trial?
Eligibility criteria for recurrent meningioma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
3
Top Sponsors
Alliance for Clinical Trials in Oncology 1 trial
University of California, San Francisco 1 trial
European Organisation for Research and Treatment of Cancer - EORTC 1 trial
Mayo Clinic 1 trial

Recruiting Clinical Trials

NCT02523014 Phase 2
Recruiting

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Enrollment
124 pts
Location
United States
Sponsor
Alliance for Clinical Trials i...
View Trial →
NCT06557512
Recruiting

Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma

Enrollment
23 pts
Location
United States
Sponsor
University of California, San ...
View Trial →
NCT06326190 Phase 2
Recruiting

177Lu-DOTATATE for Recurrent Meningioma

Enrollment
136 pts
Location
Austria, France, Nor...
Sponsor
European Organisation for Rese...
View Trial →
NCT04082520 Phase 2
Recruiting

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

Enrollment
42 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology